Dr. Panella is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1926 Alcoa Hwy
Ste 410
Knoxville, TN 37920Phone+1 865-305-8780Fax+1 865-305-8199
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1986 - 1989
- UMass Chan Medical SchoolResidency, Internal Medicine, 1983 - 1986
- University of Tennessee Health Science Center College of MedicineClass of 1983
Certifications & Licensure
- TN State Medical License 1991 - 2025
- NC State Medical License 1986 - 1992
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- Join now to see all
Publications & Presentations
PubMed
- First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study.Oleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, Mario Mandalà, Mariia Kukushkina
European Journal of Cancer. 2024-12-01 - Fusion Identified in a Patient with Medullary Thyroid Carcinoma.Omar Alsharif, Timothy Panella, Laurentia Nodit, Mimi I Hu
Thyroid. 2023-06-01 - 11 citationsSTARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectableV600-mutant melanoma.Dirk Schadendorf, Reinhard Dummer, Caroline Robert, Antoni Ribas, Ryan J Sullivan
Future Oncology. 2022-06-01
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: